Short Interest in BioStem Technologies, Inc. (OTCMKTS:BSEM) Expands By 38.8%

BioStem Technologies, Inc. (OTCMKTS:BSEM) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 191,200 shares, an increase of 38.8% from the December 15th total of 137,800 shares. Based on an average trading volume of 98,300 shares, the short-interest ratio is presently 1.9 days.

BioStem Technologies Trading Up 0.8 %

BSEM stock traded up $0.12 during mid-day trading on Thursday, reaching $15.72. The company’s stock had a trading volume of 21,158 shares, compared to its average volume of 51,516. The company’s 50 day moving average is $15.38 and its two-hundred day moving average is $12.63. BioStem Technologies has a fifty-two week low of $4.41 and a fifty-two week high of $28.26. The stock has a market cap of $261.74 million, a PE ratio of 23.12 and a beta of -0.53.

BioStem Technologies (OTCMKTS:BSEM) last released its earnings results on Tuesday, November 12th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. The business had revenue of $82.56 million for the quarter, compared to analyst estimates of $78.22 million. On average, analysts forecast that BioStem Technologies will post 1.41 earnings per share for the current fiscal year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.